This site became the new on June 19th. Learn more.
Show more Menu IMPORTANT: Listing of a study on this site does not reflect endorsement by the National Institutes of Health. Talk with a trusted healthcare professional before volunteering for a study. Read more... Menu IMPORTANT: Talk with a trusted healthcare professional before volunteering for a study. Read more... Menu
Give us feedback

MASCOT : Multicenter Asia Study in Adjuvant Treatment of Colon Cancer With OxaliplaTin/5FU-LV

This study has been completed.
Information provided by:
Sanofi Identifier:
First received: December 6, 2005
Last updated: September 14, 2009
Last verified: September 2009
Safety & tolerability of FOLFOX4 regimen in the adjuvant treatment of colon cancer in Asian patients

Condition Intervention Phase
Colonic Neoplasms Drug: oxaliplatin Phase 4

Study Type: Interventional
Study Design: Allocation: Non-Randomized
Intervention Model: Single Group Assignment
Masking: None (Open Label)
Primary Purpose: Treatment
Official Title: Multicenter Asia Study in Adjuvant Treatment of Colon Cancer With OxaliplaTin/5FU-LV

Resource links provided by NLM:

Further study details as provided by Sanofi:

Primary Outcome Measures:
  • Occurrence of dose-limiting toxicity [ Time Frame: from the inform consent signed up to the end of the study ]

Secondary Outcome Measures:
  • Occurrence of one or more adverse event in a patient [ Time Frame: From the Informed Consent Form (ICF) signature to the end of the study ]
  • Overall distribution of intensity of adverse events [ Time Frame: from the inform consnet signed up to the end of the study ]
  • Occurrence of particular adverse events and their intensities [ Time Frame: from the inform consent signed up to the end of the study ]
  • Percent of patients completing study treatment [ Time Frame: from the inform consent signed up to the end of the study ]
  • Percent of patients with grade 1, 2 and 3 neuropathy [ Time Frame: at 28 days, 6 months and 12 months after last chemotherapy administration. ]
  • Percent of intended dose delivered for 5-FU/LV and Oxaliplatin [ Time Frame: from the informed consent signed up to the end of the study ]
  • Delays in scheduled dosing [ Time Frame: During the study conduct ]
  • Dose intensity, as expressed as the amount of 5-FU/LV and Oxaliplatin administered divided by the duration of treatment [ Time Frame: during the study conduct ]
  • •Survival Analysis •Laboratory assay and vital signs ECOG and KPS [ Time Frame: during the study conduct ]
  • Long term toxicity [ Time Frame: during the study conduct ]

Study Start Date: August 2004
Primary Completion Date: June 2005 (Final data collection date for primary outcome measure)

Ages Eligible for Study:   18 Years to 75 Years   (Adult, Senior)
Sexes Eligible for Study:   All
Accepts Healthy Volunteers:   No

Inclusion Criteria:

  • Histologically proven stage Dukes " B2 " (stage II: T3-T4 N0 M0) and " C " (stage III: any T N1-2 M0) colon carcinoma. The inferior pole of the tumor must be above the peritoneal reflection (> 15 cm from the anal margin).
  • Patients must have undergone complete resection of the primary tumor without gross or microscopic evidence of residual disease
  • Patients must be entered in the study in order to start treatment within 7 weeks after surgery
  • Age 18-75 years old
  • Performance Status ≤ 2 (Karnofsky > or = 60%)
  • No previous chemotherapy, immunotherapy or radiotherapy
  • No biological major abnormalities :Absolute neutrophil count > 1.5 x 10^9/l,Platelets ≥ 100 x 10^9/l,Serum creatinine ≤ 1.25 times the upper limit of normal, total bilirubin, ASAT / ALAT < 2 times the upper limit of the normal range,carcinoembryonic antigen < 10 ng/ml.
  • Documentation of a negative pregnancy test must be available for premenopausal women with intact reproductive organs
  • Men and women who are fertile must use a medically acceptable contraceptive throughout the treatment period and for 3 months following cessation of treatment with oxaliplatin. Subjects must be made aware, before entering this trial of the risk of becoming pregnant or in fathering children
  • Signed informed consent obtained prior to study entry

Exclusion criteria

  • Pregnant or lactating women
  • Women of child bearing potential not using a contraceptive method
  • Previous cancer of the colon or rectum
  • Previous malignancies other than adequately treated in situ carcinoma of the uterine cervix or basal or squamous cell carcinoma of the skin, unless there has been a disease-free interval of at least 10 years
  • Participation in another clinical trial with any investigational drug within 30 days prior to randomization
  • Peripheral neuropathy (NCI CTC [National Cancer Institute Common Toxicity Criteria] > or = Grade I)
  • Uncontrolled congestive heart failure or angina pectoris, or hypertension or arrhythmia
  • History of significant neurologic or psychiatric disorders
  • Active infection

The above information is not intended to contain all considerations relevant to a patient's potential participation in a clinical trial.

  Contacts and Locations
Choosing to participate in a study is an important personal decision. Talk with your doctor and family members or friends about deciding to join a study. To learn more about this study, you or your doctor may contact the study research staff using the Contacts provided below. For general information, see Learn About Clinical Studies.

Please refer to this study by its identifier: NCT00263055

Beijing, China
Hong Kong
Hong Kong, Hong Kong
Korea, Republic of
Seoul, Korea, Republic of
Taipei, Taiwan
Bangkok, Thailand
Sponsors and Collaborators
Study Director: Claude Valterio, MD Sanofi
  More Information

Responsible Party: Medical Affairs Study Director, sanofi-aventis Identifier: NCT00263055     History of Changes
Other Study ID Numbers: R_9262
Study First Received: December 6, 2005
Last Updated: September 14, 2009

Additional relevant MeSH terms:
Colonic Neoplasms
Colorectal Neoplasms
Intestinal Neoplasms
Gastrointestinal Neoplasms
Digestive System Neoplasms
Neoplasms by Site
Digestive System Diseases
Gastrointestinal Diseases
Colonic Diseases
Intestinal Diseases
Antineoplastic Agents processed this record on September 20, 2017